tiprankstipranks
Aerovate Therapeutics reports Q3 EPS (71c), consensus (69c)
The Fly

Aerovate Therapeutics reports Q3 EPS (71c), consensus (69c)

The company said, “We expect that our cash, cash equivalents and available-for-sale securities will be sufficient to fund our operations into 2026, based on our current operating plan.”

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

See the top stocks recommended by analysts >>

Read More on AVTE:

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100
Bitcoin

Popular Articles